2330 enters the final stretch before its July 16 Q2 results at TWD 2,490 — up 3.75% on the week and more than 10% over the past month — with borrow costs now firmly settled and the stock trading at a valuation that prices in a strong print.
The borrow story has fully normalised. After the spike to nearly 6% in early June and the subsequent collapse documented in the prior two notes, cost to borrow has continued drifting lower — now at 0.39%, down 38% week-on-week and nearly half its level from a month ago. That is the quietest the lending market has been in the entire data window. Availability remains at the ORTEX platform ceiling, effectively unlimited, and short interest as a percentage of the free float is negligible. The lending pool is telling the same story it has told since the June episode resolved: there is no organised short position being built against the domestic listing. Positioning looks as clean as it gets for a stock of this size.
The valuation now reflects the rally. A trailing P/E of 21.9x and a price-to-book of 7.2x have both expanded over the past month — the P/E up roughly 0.9 turns in 30 days, the PB up 0.27 turns. EV/EBITDA has moved in the opposite direction, easing to 14.3x, suggesting earnings growth is absorbing some of the multiple expansion. The ORTEX short score sits at 25.0, among the least bearish 3% of all stocks in the universe — a ranking that has been stable for the past two weeks, consistent with the borrow and short interest data. Analyst data in the snapshot is too dated to be actionable, but the prior TSM ADR note established that the US-listed shares had already run through consensus targets by June 18. The domestic listing, up a further 3.75% since then, has added to that overrun.
Institutional flows add a constructive backdrop without being dramatic. BlackRock added roughly 33 million shares in the most recent reporting period, Capital Research added 9 million, and Fidelity added over 5 million — all incremental additions rather than step-change repositioning. The National Development Fund and Singapore's sovereign vehicle remain anchored at their long-standing levels. There are no signs of major rotation out of the name at the institutional level. On the insider side, recent activity is modest: a VP bought 1,000 shares on June 22 at the equivalent of $79, a small but directionally consistent signal following similar small-lot purchases by other VPs in March and May.
Earnings reactions have been muted in the recent cycle. The April print produced a 2.4% one-day decline with no meaningful follow-through over five sessions — a pattern that suggests the market is treating TSMC results as confirmation rather than catalyst, with the stock already priced for the trajectory. Peer moves on the week were mixed: 3711 on the TSEC gained 12.2% while 2449 added 17.3%, both outpacing TSMC's 3.75% — while 7729 and 4369 fell 4.4% and 3.2% respectively, a split that reflects divergent positioning across the Taiwan semiconductor complex rather than a uniform risk-on move.
With Q2 results three weeks out, the focus narrows to revenue growth confirmation in advanced nodes, any update on Arizona fab utilisation, and whether management guidance is sufficient to justify a multiple that has expanded materially since April.
See the live data behind this article on ORTEX.
Open 2330 on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
